###### Strengths and limitations of this study

-   Based on the studies in this systematic review, there is clear evidence that female genital mutilation/cutting (FGM/C) entails harms to women\'s physical health throughout their life, from the moment of cutting as an infant or child, to sexuality and childbirth in adulthood.

-   The precise estimation of the frequency and risk of complications was not feasible because of the small sample sizes and varying methods of the studies.

-   However, the consistency of results with increased risk of several physical harms in women with genital modification is robust.

-   Therefore, efforts should be expended in safeguarding girls and women against the physical risks of FGM/C and caring for those who suffer from its consequences.

Introduction {#s1}
============

The centuries-old practice of female genital mutilation/cutting (FGM/C), also known as female circumcision, is a culturally sanctioned practice[@R1] [@R2] that consists of "all procedures involving partial or total removal of the female external genitalia or other injury to the female genital organs for non-medical reasons."[@R1] According to the WHO typology, there are three main types: type I (clitoridectomy), type II (excision), type III (infibulation or pharaonic circumcision), and type IV, which is used to describe all other harmful procedures to the female genitalia in the absence of medical necessity.[@R1] Types I--III and unaltered external female genitalia are depicted in [figure 1](#BMJOPEN2014006316F1){ref-type="fig"}. The nomenclature for the practice varies across regions, ideological perspectives and research frames, and we use the expression preferred by UNICEF and UNFPA, two central policymakers in the global effort to end the practice, 'female genital mutilation/cutting' (FGM/C).[@R2] Wade explains that Western efforts to end FGM/C since the early 1970s has relied primarily on two frames that have influenced the discourse of FGM/C and, in turn, the ideological contestation over the practice.[@R3] In addition to the women\'s right frame, a dominant frame has been that the practice involves physical and mental harm.

![Illustration of unaltered external female genitalia and female genital mutilation/cutting (FGM/C) types I--III. From top left: unaltered external female genitalia, type I (clitoridectomy), type II (excision) and type III (infibulation).](bmjopen2014006316f01){#BMJOPEN2014006316F1}

Indeed, for close to a century, observational studies, supported by biological theories, have suggested a negative association between FGM/C and various health outcomes. Such studies have been summarised in a handful of reviews. Epidemiologist and medical anthropologist Obermeyer first reviewed and critiqued the available literature on FGM/C until 1996, and next summarised the subsequent literature from 1997 to 2002.[@R4] [@R5] Another early review examined primary data on health complications after FGM/C with particular emphasis on sequelae in childbirth.[@R6] Recently, Iavazzo *et al\'s*[@R7] review explored the clinical evidence for an association between FGM/C and infections. The first systematic review in this field---addressing the social, psychological and sexual consequences of FGM/C---critically reviewed and extracted data and analysed 17 comparative studies.[@R8] [@R9] While much of this research suggests a harmful effect of FGM/C on women\'s health, the findings from observational studies and non-systematic reviews are equivocal. Additionally, some commentators have questioned the evidence for many of the claimed short-term and long-term medical consequences of FGM/C, such as quality of sex life, obstetric complications and infections.[@R10]

We aimed to systematically review the evidence for the range of physical health risks associated with FGM/C by summarising the findings from three technical systematic review reports detailing the association.[@R11]

Methods {#s2}
=======

We conducted a systematic review of the physical health risks and consequences of female genital modification in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and PRISMA (Preferred Reporting Items for Systematic reviews and meta-Analyses) guidelines,[@R14] [@R15] using a predetermined protocol (PROSPERO, number CRD42012001915). The full details of the systematic review including the search strategies, risk of bias assessment and analysis are found in three technical reports.[@R11]

Search strategy {#s2a}
---------------

The search strategy was developed and undertaken by an experienced search specialist. Fifteen international electronic literature databases were searched to identify research published between inception and January 2012, with Medical Subject Headings descriptors and keywords such as infibulation, applying neither methodology search filters nor language or other search restrictions. The search strategy for MEDLINE (Ovid MEDLINE In-Process & Other Non-Indexed Citations 1946 to 20 January 2012) is shown: Circumcision, Female/((female\$ or wom\#n or girl\$1) adj3 (mutilation\$ or circumcis\$ or cutting\$)).tw."fgm/c".tw.((removal\$ or alteration\$ or excision\$) adj6 female genital\$).tw.pharaonic circumcision\$.tw.sunna.tw.(clitoridectom\$ or clitorectom\$).tw.(infibulat\$ or reinfibulat\$ or deinfibulat\$).tw.or/1--8

One reviewer (RCB) manually screened the bibliographies of published reviews on FGM/C and all included studies for additional qualifying studies. RCB did additional searches for the relevant grey literature and unpublished studies in OpenGrey, OpenSigle, OAIster, browsed websites of six international organisations that are engaged in projects regarding FGM/C, and communicated with experts in the field.

Selection of studies and extraction of data {#s2b}
-------------------------------------------

Studies retrieved were eligible for inclusion if they satisfied all our criteria: Be an empirical quantitative study with or without a comparison group published in any language that presented original quantitative data for physical health outcomes in women who had undergone any type of FGM/C as defined by the WHO.[@R1] All physical health outcomes were eligible, including but not limited to death, infections, infertility, fistula, pain, urinary complications, shock (primary outcomes), and bleeding/haemorrhage, menstrual complications, obstetric complications, vaginal calculus formation, cysts, tissue injury, fractured/displaced bones, urethral meatal stenosis/ urethral stricture, abscesses, keloid and other scarring (secondary outcomes). We applied the following exclusion criteria: Qualitative studies, studies without a quantitative measure of a physical consequence of FGM/C, and all genital modifications not captured by the WHO stated FGM/C definition.

Screening, quality appraisal and data extraction were independently undertaken by two investigators (RCB and VU), with discrepancies resolved by consensus. The two investigators confirmed the eligibility of first titles and abstracts and then full texts. Quality assessment of the identified studies was undertaken as recommended in the Cochrane Handbook, using design specific checklists based on the User\'s Guide framework.[@R16] This was done at the study level. The investigators extracted study information and data onto a standardised data collection form, which had been piloted. Data extracted included publication details, study design, sample characteristics, FGM/C characteristics, methods of outcome measurement and health consequences. We contacted authors for additional data or clarification where needed.

Statistical analysis {#s2c}
--------------------

We grouped the data according to outcomes across the studies, keeping the outcome categories or labels as reported in each individual study. We estimated associations for dichotomous unadjusted variables in terms of relative risks (RR) with 95% CIs. ORs and 95% CIs were used for case--control studies and adjusted analyses. Outcomes that were sufficiently similar across studies, and reasonable resistant to biases and relatively homogeneous in this respect, were aggregated in meta-analyses. When available, we pooled adjusted estimates; otherwise, we pooled the unadjusted estimates based on crude data from the individual studies. ORs and RRs greater than one indicate an increased risk of complications with FGM/C; if less than one, they indicate a decreased risk.

We anticipated heterogeneity between studies due to different study methodologies and geographical and population differences. Heterogeneity was examined using the χ^2^ test and I^2^ statistic. We used a random-effects model to account for within-study and between-study heterogeneity.

In random-effects meta-analysis, the weight assigned to each included study is adjusted to include a measure of variation (τ^2^) in the effects reported between studies. We used the Mantel-Haenszel method for unadjusted dichotomous data, and for adjusted data we used the generic inverse-variance method, in which weight is given to each study according to the inverse of the variance of the effect, to minimise uncertainty about the pooled effect estimates. Analyses were done with Review Manager (V.5.2.8).

We applied the instrument Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the extent to which we have confidence in the effect estimates.[@R17] GRADE is a transparent and systematic approach to grading our confidence in the evidence. For resource reasons, we used GRADE only for outcomes eligible for meta-analysis.

Those of us who did the systematic review were not masked to the authors, institution or journal of publication. The use of non-masked reviewers is accepted practice in meta-analyses and has been shown not to bias results.[@R18] In line with recommendations,[@R14] results from the studies deemed to have the highest internal validity were given preference. In this communication, we present all studies that reported outcomes for differentially FGM/C exposed groups of women, that is, studies with a comparison group.

Role of the funding source {#s2d}
--------------------------

Norad and the WHO commissioned the study and the latter contributed some funding (\$10 000). The commissioners of the systematic review had no role in the study design, data collection, data analysis, data interpretation or writing of the report. RCB had final responsibility for the decision to submit for publication.

Results {#s3}
=======

Our search strategy identified 5109 unique publications, the titles and abstracts of which were screened for inclusion. The full text of 12 publications could not be located, while 431 articles were retrieved, of which 185 met the inclusion criteria ([figure 2](#BMJOPEN2014006316F2){ref-type="fig"}).

![PRISMA flow diagram for selection of literature.](bmjopen2014006316f02){#BMJOPEN2014006316F2}

The 185 included studies were of varying publication types, published between 1927 and 2011, and from 42 different countries (see online supplementary appendix 1). There were 13 studies from the Middle East, 43 from a Western country, and 129 from Africa. Twenty different African countries were represented. The FGM/C participants in studies from a Western country originated in the majority of cases from Somalia, and in the remaining cases they originated from another African country where FGM/C is commonly practised. Overall, the 185 studies involved 3.17 million female participants, from infants to women in their 70s, with a mean age of approximately 30. With respect to the FGM/C characteristics, the majority of women had genital alteration that involved the cutting and removal of portions of the external female genitalia, without stitching, corresponding to either type I or type II. The procedure had in the absolute majority of cases been undertaken in early childhood, usually before the age of 10, by a traditional circumciser. A total of 75 different outcomes were extracted.

In this overview, we present key physical health complications of FGM/C in a life course perspective. Except for some immediate outcomes, these key outcomes derive from comparative studies, that is, women with FGM/C are compared to women without FGM/C with respect to an outcome in a cohort, case--control or cross-sectional study ([table 1](#BMJOPEN2014006316TB1){ref-type="table"}). We prioritise the presentation of studies with clinically measured and adjusted outcome data, but note also the best available evidence for additional key outcomes, largely immediate complications. [Table 1](#BMJOPEN2014006316TB1){ref-type="table"} shows the 57 studies with the best available evidence regarding the physical health sequelae of FGM/C (comparative cohort, case--control, cross-sectional studies).[@R19] About 40% of the outcomes were self-reported primarily by adult women, although the great majority of the obstetric and some genitourinary outcomes were clinically measured. The meta-analytical results that are based on unadjusted estimates are presented in [figure 3](#BMJOPEN2014006316F3){ref-type="fig"}, and those based on adjusted estimates are shown in [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}.

###### 

Summary of included comparative studies (N=57)

  Author, year                  Study design                              Quality    N           Country                    Outcomes (assessment type)
  ----------------------------- ----------------------------------------- ---------- ----------- -------------------------- -------------------------------------------------------------
  Adinma, 1997[@R19]            Cross-sectional                           Low        256         Nigeria                    Obstetric (self-report)
  Almroth, 2005a[@R20]          Case--control                             High       279         Sudan                      Infertility (clinical)
  Almroth, 2005b[@R21]          Cross-sectional                           High       255         Sudan                      Genitourinary (clinical)
  Alsibiani, 2010[@R22]         Cross-sectional                           Moderate   260         Saudi Arabia               Sexual (self-report)
  Balk, 2000[@R23]              Based on the Sudan DHS 1990               Moderate   5856        Sudan                      Infertility (self-report)
  Berardi, 1985[@R24]           Prospective                               Low        852         France                     Obstetric (clinical)
  Bohoussou, 1986[@R25]         Cross-sectional                           Low        4935        Ivory Coast                Obstetric (unclear)
  Brewer, 2007[@R26]            Based on the Kenya DHS 2003               High       539         Kenya                      HIV/STIs (clinical)
  Browning, 2010 [@R27]         Retrospective cohort                      Moderate   492         Ethiopia                   Genitourinary, obstetric (clinical)
  Chibber, 2011[@R28]           Prospective                               Low        4800        Unclear                    Obstetric (clinical)
  De Silva, 1989[@R29]          Prospective                               Low        2157        Saudi Arabia               Genitourinary, obstetric (clinical)
  El Dareer, 1983[@R30]         Cross-sectional                           Low        3210        Sudan                      Immediate, genitourinary (self-report)
  el Defrawi, 2001[@R31]        Cross-sectional                           Moderate   250         Egypt                      Genitourinary, sexual (self-report)
  Elmusharaf, 2006[@R32]        Case--control                             High       222         Sudan                      HIV/STIs (clinical)
  Elnashar, 2007[@R33]          Cross-sectional                           Low        264         Egypt                      Genitourinary, sexual, obstetric, (self-report)
  Essén, 2005[@R36]             Registry study                            Moderate   2554        Sweden                     Obstetric (clinical)
  Fillo, 2007[@R37]             Based on the Burkina Faso DHS 2003        Moderate   12 477      Burkina Faso               Genitourinary (unclear)
  Hakim, 2001[@R38]             Unclear if prospective or retrospective   Low        1481        Ethiopia                   Obstetric (clinical)
  Holmgren, 2003[@R39]          Cross-sectional                           Moderate   857         Guinea-Bissau              HIV/STIs (clinical)
  Inhorn, 1993[@R40]            Case--control                             High       190         Egypt                      Infertility (clinical)
  Jackson, 2005[@R41]           Cross-sectional                           Low        ?           Ghana                      Infertility (self-report)
  Johnson 2005[@R42]            Registry study                            Low        5416        USA                        Obstetric (clinical)
  Jones, 1999-I[@R43]           Cross-sectional                           Low        1920        Burkina Faso               Genitourinary (clinical), obstetric (self-report)
  Jones, 1999-II [@R43]         Prospective                               Moderate   5337        Mali                       Genitourinary, obstetric (clinical)
  Kanki, 1992[@R44]             Cross-sectional                           Moderate   1710        Senegal                    HIV/STIs (clinical)
  Kaplan, 2011[@R45]            Cross-sectional                           Moderate   871         Gambia                     Immediate (self-report), genitourinary (clinical)
  Klouman, 2005[@R46]           Cross-sectional                           Moderate   396         Tanzania                   Genitourinary, HIV/STIs, infertility (clinical)
  Larsen, 2002[@R47]            Based on the Sudan DHS 1990               Moderate   5849        Sudan                      Infertility (self-report)
  Larsen 2002[@R48]             Cross-sectional                           Low        1836        Nigeria                    Obstetric (self-report)
  Larsen, 2000-I[@R49]          Based on the CAR DHS 1995                 Moderate   4388        Central African Republic   Infertility (self-report)
  Larsen, 2000-II[@R49]         Based on the Ivory Coast DHS 1995         Moderate   5930        Ivory Coast                Infertility (self-report)
  Larsen, 2000-III[@R49]        Based on the Tanzania DHS 1997            Moderate   6043        Tanzania                   Infertility (self-report)
  Larsen, 1989[@R50]            Cross-sectional                           Low        2183        Sudan                      Infertility (self-report)
  Lupo, 1999[@R51]              Registry study                            Low        114         USA                        Obstetric (unclear)
  Maslovskaya, 2009[@R52]       Based on the Kenya DHS 2003               High       3114        Kenya                      HIV/STIs (clinical)
  Millogo-Traore, 2007[@R53]    Prospective                               Low        454         Burkina Faso               Obstetric (clinical)
  Morison, 2001[@R54]           Cross-sectional                           High       1157        Gambia                     Genitourinary, sexual, HIV/STIs, infertility (clinical)
  Msuya, 2002[@R55]             Cross-sectional                           High       379         Tanzania                   Genitourinary, HIV/STIs (clinical)
  Ndiaye, 2010[@R56]            Cross-sectional                           Low        354         Burkina Faso               Obstetric (clinical)
  NSEO, 2002[@R34]              Cross-sectional                           Low        7765        Eritrea                    Sexual, obstetric (self-report)
  NSO, 1995[@R35]               Cross-sectional                           Low        4775        Eritrea                    Sexual, obstetric (self-report)
  Nwajei, 2003[@R57]            Cross-sectional                           Low        400         Nigeria                    Genitourinary (self-report)
  Odoi, 1997[@R58]              Cross-sectional                           Low        195         Ghana                      Sexual (self-report)
  Oduro, 2006[@R59]             Registry study                            High       5071        Ghana                      Obstetric (clinical)
  Okonofua, 2002[@R60]          Cross-sectional                           Moderate   1836        Nigeria                    Genitourinary, sexual (clinical/self-report)
  Orji, 2006[@R61]              Cross-sectional                           Low        500         Nigeria                    Obstetric (self-report)
  Pépin, 2006[@R62]             Cross-sectional                           Moderate   1026        Guinea-Bissau              HIV (clinical)
  Pépin, 1991[@R63]             Cross-sectional                           Low        345         Gambia                     HIV (clinical)
  Rushwan, 1983[@R64]           Cross-sectional                           Low        2502        Sudan                      Immediate, genitourinary, sexual, infertility (self-report)
  Shandall, 1967[@R65]          Cross-sectional                           Low        4487        Sudan                      Immediate, genitourinary (clinical/self-report)
  Slanger, 2002[@R66]           Cross-sectional                           Moderate   1107        Nigeria                    Obstetric (self-report)
  Small, 2008[@R67]             Registry study                            Low        2 179 322   Multiple                   Obstetric (clinical)
  Vangen, 2002[@R68]            Registry study                            Low        703 925     Norway                     Obstetric (clinical)
  WHO study group, 2006[@R69]   Prospective                               High       28 393      Multiple                   Obstetric (clinical)
  Wuest, 2009[@R70]             Prospective                               Low        232         Switzerland                Obstetric (clinical)
  Yount, 2007[@R71]             Based on the Kenya DHS 2003               Moderate   3167        Kenya                      HIV/STIs (clinical), obstetric (self-report)
  Yount, 2006[@R72]             Cross-sectional                           Low        1700        Egypt                      Infertility, obstetric (self-report)

Two studies are presented in Jones 1999 [@R43] (Jones 1999-I is from Mali, and Jones 1999-II is from Burkina Faso); three studies are presented in Larsen 2000 [@R49] (Larsen 2000-I is from the Central African Republic, Larsen 2000-II is from the Ivory Coast, and Larsen 2000-III is from Tanzania).

CAR, Central African Republic; DHS, Demographic and Health Survey; Quality, Methodological study quality at study level; STIs, sexually transmitted infections.

![Meta-analyses of urinary tract infection, dyspareunia, sexually transmitted infections, episiotomy (unadjusted effect estimates).](bmjopen2014006316f03){#BMJOPEN2014006316F3}

![Meta-analyses of bacterial vaginosis, HIV, prolonged labour, obstetric tears, caesarean section, instrumental delivery, obstetric haemorrhage, difficult delivery (adjusted effect estimates).](bmjopen2014006316f04){#BMJOPEN2014006316F4}

Immediate complications {#s3a}
-----------------------

In most cases of FGM/C, a girl\'s clitoris and labia are cut away, often with a crude unsterile instrument and without anaesthetics by a traditional practitioner who has little knowledge of female anatomy.[@R2] Thus, it is reasonable to assume that physiological harms such as bleeding ensue during the cutting process and the short-term postprocedure period. We identified no studies that analysed the potential statistical differences in the risk of direct, procedure-related complications between types of FGM/C. However, 56 observational studies reported on eight main types of immediate medical harms (bleeding, shock, genital tissue swelling, fever, infections and problems with urination and wound healing) on 133 515 females of various ages and types of FGM/C. The rate of immediate complications varied greatly across the studies. There were strong indications of under-reporting of immediate complications from the procedure, with some studies reporting that 90% of the girls undergoing FGM/C experienced no bleeding at all.[@R30] [@R64] However, representative studies (ie, where the participants can be assumed to represent the larger population) of moderate and high methodological quality indicated that the most common immediate complications were: excessive bleeding (median 32%, range 5--62%), urine retention (median 31%, range 8--53%), genital tissue swelling (median 15%, range 2--27%), problems with wound healing (13%) and pain (11%).[@R30] [@R73] [@R74] Girls generally suffered more than one immediate complication. We identified three clinical reports on deaths directly attributed to FGM/C.[@R75] Fourteen studies reported the number of events for different types of FGM/C separately, allowing us to estimate differences in risk across exposure groups.[@R30] [@R45] [@R64] [@R65] [@R78] Our results indicated that there might be a greater risk of immediate harms with FGM/C type III relative to types I--II. We found few, and small, differences in risk of immediate complications with FGM/C types I--II compared to type IV (generally 'nick').

Genitourinary problems {#s3b}
----------------------

With respect to the genitourinary sequelae of FGM/C, reported years and sometimes decades following the procedure, we identified 17 comparative studies.[@R21] [@R27] [@R29] [@R37] [@R43] [@R45] [@R46] [@R54] [@R55] [@R57] [@R60] [@R64] [@R65] In total, the studies included 38 390 women. The most frequently measured outcomes were genital tissue damage, vaginal discharge and itching, urological complications and infections. Many sequelae were examined in only one or a few studies and/or they were relatively rare events, such as keloids and abscesses. Analyses were thus often unable to establish whether there were statistically significant differences between the groups being compared and the CIs were wide. As a result, there was insufficient information available from the studies to assess difference in risk relative to FGM/C exposure. The results were inconclusive with respect to: scarring, keloids, abscesses, fistulae, damaged tissue (perineum, anal sphincter), disfigurement, vaginal obstruction and cysts.

According to four cross-sectional studies (n=3657), there was a trend for a greater risk of vaginal discharge and itching with FGM/C (adjusted ORs (AOR) from 0.94 to 2.81).[@R33] [@R54] [@R57] [@R60] Urological long-term complications were reported in four comparative studies (n=3611), none of which could establish a statistically significant difference, either in unadjusted analyses (RRs from 0.85 to 1.78) or in adjusted analyses (AORs from 0.80 to 1.29), between women with FGM/C and women with no FGM/C.[@R27] [@R33] [@R54] [@R60] However, results from two studies of moderate to high methodological study quality indicated a trend for a greater risk of burning or painful urination with FGM/C (RR=2.56, 95% CI 0.80 to 8.22; RR=1.66, 95% CI 0.96 to 2.85).[@R33] [@R60] Menstrual problems were reported in five studies (n=6564).[@R30] [@R31] [@R33] [@R54] [@R64] They showed a trend towards a greater risk of menstrual problems with FGM/C: dysmenorrhoea (RR=1.44, 95% CI 1.11 to 1.86), difficulty in menstruation (RR=1.02, 95% CI 0.06 to 16.28), menstrual problems (RR=0.77, 95% CI 0.61 to 0.97), irregular menses (RR=2.56, 95% CI 1.48 to 3.45) and difficulty in passing menstrual blood (RR=1.75, 95% CI 0.78 to 3.93).

Ten comparative studies (n=28 940) reported results concerning long-term genitourinary infections.[@R21] [@R29] [@R30] [@R37] [@R43] [@R46] [@R54] [@R55] [@R64] [@R65] Owing to few studies and the low number of events, the findings were inconclusive for the following outcomes: chronic pelvic infections, reproductive tract infections, genital infections and vaginitis. However, in adjusted analyses, two studies of low to moderate methodological quality found a statistically higher risk of reproductive tract infections (AOR=1.54, 95% CI 1.08 to 2.21) and genital infections (AOR=1.72, 95% CI 1.02 to 2.92) with FGM/C.[@R37] [@R43] Meta-analyses showed a greater risk of urinary tract infections (RR=3.01, 95% CI 1.42 to 6.38; GRADE: very low; [figure 3](#BMJOPEN2014006316F3){ref-type="fig"})[@R21] [@R29] [@R30] [@R64] [@R65] and bacterial vaginosis (AOR=1.68, 95% CI 1.28 to 2.22; GRADE: very low) with FGM/C ([figure 4](#BMJOPEN2014006316F4){ref-type="fig"}).[@R46] [@R54]

Painful sexual intercourse {#s3c}
--------------------------

Dyspareunia (painful sexual intercourse) was reported in six studies (n=6204).[@R31] [@R33] [@R54] [@R58] [@R60] [@R64] The meta-analysis, presented in [figure 3](#BMJOPEN2014006316F3){ref-type="fig"}, showed an increased risk of dyspareunia with FGM/C (RR=1.53, 95% CI 1.20 to 1.97; GRADE: very low). Correspondingly, results from two nationally representative studies from Eritrea (n=12 540) indicated a 'dose--response' relationship, with a lower risk of problems during sexual relations with FGM/C types I--II relative to type III (RR=0.19, 95% CI 0.16 to 0.24; RR=0.44, 95% CI 0.27 to 0.72).[@R34] [@R35]

HIV and sexually transmitted infections {#s3d}
---------------------------------------

HIV and sexually transmitted infections (STIs) were clinically examined in one case--control study and 10 cross-sectional studies (n=12 912).[@R26] [@R32] [@R39] [@R44] [@R46] [@R52] [@R54] [@R55] [@R62] [@R63] [@R71] The case--control study could not establish a difference between FGM/C and no FGM/C regarding STIs (AOR=1.13, 95% CI 0.73 to 1.77).[@R32] Similarly, the meta-analysis of cross-sectional studies failed to establish a difference (RR=1.07, 95% CI 0.75 to 1.53; GRADE: very low; [figure 3](#BMJOPEN2014006316F3){ref-type="fig"}).[@R54] [@R55] [@R71] As shown in [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}, also the meta-analysis for HIV, based on four studies which presented adjusted data, failed to establish a difference relative to FGM/C (AOR=0.95, 95% CI=0.54 to 1.67; GRADE: very low).[@R44] [@R46] [@R62] [@R71]

Infertility {#s3e}
-----------

Twelve studies presented data on infertility (n=36 473).[@R20] [@R23] [@R40] [@R41] [@R46] [@R47] [@R48] [@R50] [@R54] [@R64] Two case--control studies of high methodological quality examined whether FGM/C was a predictor for infertility. The case--control study from Sudan could not establish an association between infertility and FGM/C (AOR=1.77, 95% CI 0.52 to 7.10).[@R20] Similarly, the case--control study from Egypt could not establish a difference between FGM/C type II and type I with respect to tubal factor infertility (AOR=1.9, 95% CI 0.8 to 4.2).[@R40] The available evidence did not allow us to conclude whether women were more likely to be infertile if they were cut by a traditional than a medical circumciser (AOR=2.1, 95% CI 0.8 to 5.7).[@R40] Ten cross-sectional studies examined infertility in women with and without FGM/C. The association between FGM/C and infertility varied, both in unadjusted analyses (effect estimates ranged from 0.34 to 3.67) and adjusted analyses (AORs from 0.99 to 2.76). Specifically, the results of the two clinical studies of moderate to high methodological quality did not establish a greater risk with FGM/C (OR=1.3, 95% CI 0.7, 2.7; OR=1.05, 95% CI 0.65 to 1.67. Of eight adjusted estimates, two reached significance. These are not shown here because the CIs were not provided in the publications).[@R46] [@R54]

Obstetric outcomes {#s3f}
------------------

Obstetric events (prolonged labour, tears/lacerations, caesarean section, episiotomy, instrumental delivery, haemorrhage, difficult labour) were reported in 26 comparative studies (2.97 million women).[@R19] [@R24] [@R33] [@R38] [@R42] [@R43] [@R48] [@R51] [@R53] [@R56] [@R59] [@R61] [@R66][@R69] [@R71] [@R72] Seven of these were prospective.[@R24] [@R28] [@R29] [@R43] [@R53] [@R69] [@R70] Eight studies reported adjusted data, with the number and types of confounders varying greatly across studies (detailed in the study under review).[@R28] [@R36] [@R42] [@R43] [@R48] [@R66] [@R68] [@R69]

Data on prolonged labour were reported in six studies.[@R28] [@R29] [@R36] [@R48] [@R53] [@R68] The meta-analysis of adjusted estimates from four studies showed a significantly greater risk of prolonged labour with FGM/C (AOR=1.49, 95% CI 1.01 to 2.19; GRADE: low; [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}).[@R28] [@R36] [@R48] [@R68] There was one prospective study, of low to moderate methodological quality, that reported an adjusted estimate for prolonged labour, the result of which was concordant with the meta-analysis (AOR=2.40, 95% CI 1.40 to 2.80).[@R28] Regarding obstetric tears/lacerations, the meta-analysis of four studies which presented adjusted data showed an AOR of 1.39 (95% CI 0.99 to 1.95; GRADE: very low; [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}).[@R42] [@R48] [@R66] [@R68] No prospective studies presented adjusted estimates for obstetric tears.

There were 15 studies with data on caesarean section.[@R24] [@R25] [@R28] [@R29] [@R33] [@R42] [@R48] [@R56] [@R59] [@R66] Five studies reported adjusted estimates, the pooled estimate of which resulted in an AOR of 1.32 (95% CI 0.97 to 1.80; GRADE: very low). Restricting the meta-analysis to the two prospective studies established a significant difference between groups (AOR=1.60, 95% CI 1.33 to 1.91; GRADE: low), indicating a greater risk of caesarean section among women with FGM/C ([figure 4](#BMJOPEN2014006316F4){ref-type="fig"}).[@R28] [@R69] As with the other obstetric outcomes, the study-level results were inconsistent regarding episiotomy. Eleven studies reported on episiotomy,[@R19] [@R24] [@R29] [@R33] [@R38] [@R48] [@R53] [@R56] [@R66] [@R69] [@R70] but there was only one (retrospective) study with adjusted data.[@R48] The result from the most comprehensive model in this study (ie, adjusting for the highest number of confounders) showed an AOR of 1.18 (95% CI 0.76 to 1.84). No prospective studies presented adjusted estimates for episiotomy, but we aggregated the unadjusted results from five prospective studies (n=32 088 women), finding an increased risk with FGM/C (RR=1.38; 95% CI 1.14 to 1.67; GRADE: very low; [figure 3](#BMJOPEN2014006316F3){ref-type="fig"}).[@R24] [@R29] [@R53] [@R69] [@R70]

There were nine studies with data on instrumental delivery.[@R24] [@R25] [@R29] [@R42] [@R53] [@R66] [@R70] Two (registry based) studies reported adjusted data.[@R42] [@R68] The meta-analysis for primiparous women suggested a greater risk of instrumental delivery with FGM/C (AOR=1.56, 95% CI 1.32 to 1.86; GRADE: very low), which could not be firmly established for multiparous women (AOR=1.34, 95% CI 0.80 to 2.26; GRADE: very low; [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}). We also included nine studies with data on obstetric or postpartum haemorrhage.[@R28] [@R29] [@R38] [@R42] [@R56] [@R66] [@R68] Five studies reported adjusted results, which we combined in a meta-analysis. The result indicated a greater risk with FGM/C (AOR=1.50, 95% CI 1.22 to 1.84; GRADE: very low). However, the pooled adjusted estimate based on the two prospective studies that reported adjusted data for haemorrhage failed to establish a convincing difference relative to FGM/C (AOR=1.91, 95% CI 0.89 to 4.08; GRADE: very low; [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}).[@R28] [@R69] Lastly, we included six comparative studies with data on difficult delivery.[@R28] [@R42] [@R43] [@R56] [@R66] The pooled result based on adjusted estimates from the two studies that could be combined resulted in an AOR of 1.88 (95% CI 1.06 to 3.35; GRADE: low; [figure 4](#BMJOPEN2014006316F4){ref-type="fig"}).[@R28] [@R66] A third study compared women without FGM/C with women who had FGM/C type I. The AORs were 0.17 (95% CI=0.06 to 0.52) and 0.32 (95% CI=0.19 to 0.54), which favoured not having FGM/C.[@R43] There was one prospective study with data on difficult delivery.[@R28] The estimate showed a greater risk with FGM/C (AOR=2.30, 95% CI 1.3 to 2.5).

Discussion {#s4}
==========

This systematic review provides clear evidence that FGM/C entails harms to women\'s physical health throughout their life, from the moment of cutting as an infant or child, to sexuality and childbirth in adulthood. Predictably, the most common direct, procedure-related complication includes haemorrhage, most likely resulting from laceration of the internal pudendal artery or the clitoral artery. It is difficult to determine the number of females who die from procedure-related complications. Only a few studies reported death, but highly publicised fatalities from FGM/C heighten the awareness of the possible harms posed by the procedure, such as three recent cases in Egypt and Kenya.[@R88]

We found several long-term consequences of FGM/C, including increased risks of urinary tract infections, bacterial vaginosis, dyspareunia and obstetric complications. Studies have been published since we conducted our search, and they corroborate our findings.[@R91] The identified risks from FGM/C are also supported by biological rationales for the associations. As explained by experts,[@R21] [@R54] [@R92] any alteration of the natural anatomy of the vulva, such as removal of the protective labia minora, can lead to structural and physiological changes, including trauma to the urethra, adjacent tissues and nerves at the time of the procedure as well as formation of scars and flaps of skin during the healing process.

FGM/C is a non-therapeutic procedure, which by definition does not treat an underlying pathological process, but rather forms an actionable risk factor for several morbidities. As public policy discussions gain momentum on how to prevent FGM/C, our findings about the health complications could be communicated to practising communities, health practitioners, government bodies, international health organisations and other stakeholders. Global policy efforts should be expended in safeguarding females against the physical risks of FGM/C and, as emphasised by the United Nations agencies,[@R1] in upholding their bodily integrity and furthering their human rights. Worldwide, about 125 million girls and women alive today live with FGM/C, and every year another three million girls in the countries where the practice is concentrated are at risk of undergoing the practice.[@R2] [@R99] Caring for girls and women who suffer from its consequences and research into the best and most acceptable treatment and care are important.

This systematic review offers the most comprehensive and scientific evidence presently available on the range of physical health complications from FGM/C---other reviews are non-systematic and limited in scope[@R4]---but a complete understanding is hindered by data gaps. The search was executed in 2012 and it is possible that our systematic review is subject to publication bias. The discrepancy between the large number of records identified in our search and the 185 studies included attest to the literature on FGM/C being longer on opinion and polemic and considerably shorter on data. We identified only three case--control studies and seven prospective studies. Many included studies had low methodological study quality; many outcomes were reported in just a few studies, and event rates in several studies were low. Thus, most data are of low quality, which partly results from the nature of the study question, which is difficult to answer by means of rigorous research methods. Additionally, the measurement and reporting of exposure, outcome and confounders were done with varying precision in the included studies, and although we did subgroup and random-effects analyses, these could not fully account for the observed heterogeneity across studies. Thus, the summary estimates for all outcomes should be interpreted cautiously. Some of the above possible sources of biases would tend to bias our summary estimates towards the null, and are likely to lead to too conservative estimates of the true harmful association of FGM/C with physical health. For example, research on male circumcision has found that adverse events are recorded less frequently in retrospective than prospective studies.[@R100] Owing to gaps in the evidence base, precise estimation of frequency and risk of complications is not possible. However, irrespective of the exact size of the greater risk from FGM/C, the consistency of results with increased risk of several physical harms in women with genital modification is robust, and even the lowest increase in risk of complications is undesirable from a woman\'s health perspective.

Conclusion {#s5}
==========

The evidence base on the physical health complications of FGM/C, which covers over half a century of research from more than 20 countries in Africa and beyond, shows that FGM/C is associated with an increased risk of health complications, especially urinary tract infections, bacterial vaginosis, painful sexual intercourse and obstetric difficulties. Further research into this question is unlikely to produce practical value. Rather, efforts should be expended in safeguarding girls and women against the physical risks of FGM/C and caring for those who suffer from its consequences.
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